150514-60-6

Basic information

• Product Name: (4-AMINO-PIPERIDIN-1-YL)-PHENYL-METHANONE
• Synonyms: (4-AMINO-PIPERIDIN-1-YL)-PHENYL-METHANONE;1-Benzoylpiperidin-4-amine
• CAS NO: 150514-60-6
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.27
• Mol File: 150514-60-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 355.5 °C at 760 mmHg
• Flash Point: 168.8 °C
• Appearance: /
• Density: 1.121 g/cm³
• CAS DataBase Reference: (4-AMINO-PIPERIDIN-1-YL)-PHENYL-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-AMINO-PIPERIDIN-1-YL)-PHENYL-METHANONE(150514-60-6)
• EPA Substance Registry System: (4-AMINO-PIPERIDIN-1-YL)-PHENYL-METHANONE(150514-60-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 150514-60-6(Hazardous Substances Data)

Usage

General Description

(4-AMINO-PIPERIDIN-1-YL)-PHENYL-METHANONE is a chemical compound with the molecular formula C14H18N2O. It is a substituted piperidine derivative with a phenyl-methanone group attached to the piperidine ring. (4-AMINO-PIPERIDIN-1-YL)-PHENYL-METHANONE has potential applications in pharmaceutical research and drug development due to its structural features and potential bioactivity. The presence of the amino and phenyl groups in the molecule suggests that it may have biological effects related to neurotransmitter receptors or enzyme inhibition. Further research is needed to fully characterize the properties and potential uses of (4-AMINO-PIPERIDIN-1-YL)-PHENYL-METHANONE.

Upstream product

• 24686-78-0 1-Benzoyl-4-piperidone 
• 98-88-4 benzoyl chloride 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 429677-00-9 tert-butyl N-(1-benzoylpiperidin-4-yl)carbamate 
• 577778-39-3 (4-benzylamino-piperidin-1-yl)-phenyl-methanone 

Downstream Products

• 1458639-06-9 C₂₇H₃₃N₅O₃ 
• 1458638-98-6 C₃₁H₃₅N₇O₃ 

Relevant articles and documents

Synthesis and Structure–Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents

P2X3 receptors (P2X3R) are ATP-gated ion channels predominantly expressed in C-and Aδ-fiber primary afferent neurons and have been introduced as a novel therapeutic target for neurological disorders, including neuropathic pain and chronic cough. Because of its localized distribution, antagonism of P2X3R has been thoroughly considered, and the avoidance of issues related to CNS side effects has been proven in clinical trials. In this article, benzimidazole-4,7-dione-based derivatives were introduced as a new chemical entity for the development of P2X3R antagonists. Starting from the discovery of a hit compound from the screening of 8364 random library compounds in the Korea Chemical Bank, which had an IC50 value of 1030 nM, studies of structure–activity and structure–property relationships enabled further optimization toward improving the antagonistic activities as well as the drug’s physicochemical properties, including metabolic stability. As for the results, the final optimized compound 14h was developed with an IC50 value of 375 nM at P2X3R with more than 23-fold selectivity versus P2X2/3R, along with properties of metabolic stability and improved solubility. In neuropathic pain animal models evoked by either nerve ligation or chemotherapeutics in male Sprague-Dawley rats, compound 14h showed anti-nociceptive effects through an increase in the mechanical withdrawal threshold as measured by von Frey filament following intravenous administration.

INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES

Described herein are compounds of Formula (I'), Formula (IA), Formulae (I)-(VII), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrug sthereof. The invention also provides pharmaceutical compositions of the compounds for human and veterinary use. Compounds of the present invention are useful for inhibiting bacterial growth and therefore are useful in treating and/or preventing bacterial infections. Methods of using the compounds for treating and/or preventing a bacterial infection in a subject are also described.

Chemoselective reductive alkylation of ammonia with carbonyl compounds: Synthesis of primary and symmetrical secondary amines

An efficient, general procedure for highly chemoselective reductive mono-alkylation of ammonia with ketones is reported. Treatment of ketones with ammonia in ethanol and titanium(IV) isopropoxide, followed by in situ sodium borohydride reduction, and a straightforward workup afforded primary amines in good to excellent yields. Reductive alkylation of ammonia with aldehydes, on the other hand, afforded the corresponding symmetrical secondary amines selectively.